Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239133 | 0.83 | KDR (0.41) | KDRP2RX3GRM2SCN9A | |
| SCHEMBL18249748 | 0.81 | P2RX3 (0.47) | P2RX3SCN9ALMNAHTTSMN1; SMN2 | |
| SCHEMBL20239160 | 0.80 | PGR (0.37) | KDRP2RX3PGRKDM4EALDH1A1 | |
| SCHEMBL16738663 | 0.76 | SMN1; SMN2 (0.40) | P2RX3PGRKDM4EALDH1A1LMNA | |
| SCHEMBL18249815 | 0.73 | SMN1; SMN2 (0.42) | P2RX3PGRKDM4EALDH1A1LMNA | |
| SCHEMBL20239242 | 0.73 | LMNA (0.41) | PGRKDM4EALDH1A1LMNAHTT | |
| SCHEMBL20239162 | 0.73 | P2RX3 (0.39) | KDRP2RX3PGRHPGDMET | |
| SCHEMBL20239299 | 0.72 | LOXL2 (0.57) | — | |
| SCHEMBL18249762 | 0.72 | GRM5 (0.44) | P2RX3PGRKDM4EALDH1A1LMNA | |
| SCHEMBL3262852 | 0.72 | KDR (0.61) | KDRP2RX3KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3298001-A1 | NOVEL DGAT2 INHIBITORS | Eli Lilly and Company (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187384-A1 | NOVEL DGAT2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | KDR 1382/4885P2RX3 2448/4885PGR 2121/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | KDR 1360/4885P2RX3 1822/4885PGR 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.